


PRODUCT INFORMATION



Marimastat

Item No. 14869

CAS Registry No.: 154039-60-8
Formal Name: (2S,3R)-N⁴-[(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N^{1,2}-dihydroxy-3-(2-methylpropyl)-butanediamide
Synonyms: BB-2516, KB-R8898
MF: C₁₅H₂₉N₃O₅
FW: 331.4
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Marimastat is supplied as a crystalline solid. A stock solution may be made by dissolving the marimastat in the solvent of choice, which should be purged with an inert gas. Marimastat is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of marimastat in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Description

Marimastat is a broad-spectrum matrix metalloproteinase (MMP) inhibitor (IC₅₀s = 5, 6, 230, 16, and 3 nM for MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9, respectively).¹ It also binds to a recombinantly expressed catalytic domain of human MMP-14 (MMP-14_{cat}; K_i = 2.1 nM) and inhibits gelatinases (IC₅₀s = 3–6 nM), fibroblast collagenase (IC₅₀ = 5 nM), and matrylin (IC₅₀ = 16 nM).² It inhibits peritoneal dissemination of implanted human gastric carcinoma TMK-1 cells in nude mice (18 mg/kg per day) but does not affect TMK-1 viability *in vitro*, providing only 2.64% inhibition when used at a concentration of 10 μM.³ Marimastat inhibits lymph node metastasis in an oral squamous cell carcinoma (OSCC) OSC-19 mouse xenograft model (30 mg/kg per day).⁴ It also delays tumor growth of human head and neck squamous cell SCC-1 xenografts in nude mice alone and when combined with chemoradiation when administered at a dose of 8.7 mg/kg per day.⁵ Marimastat is an inhibitor of tumor necrosis factor alpha (TNF-α) convertase (TACE), which catalyzes pro-TNF-α conversion into TNF-α (IC₅₀s = 3.8 and 7,000 nM for purified TACE and whole blood, respectively).⁶

References

1. Rasmussen, H.S. and McCann, P.P. *Pharmacol. Ther.* **75(1)**, 69-75 (1997).
2. Toth, M., Bernardo, M.M., Gervasi, D.C., et al. *J. Biol. Chem.* **275(52)**, 41415-41423 (2000).
3. Kimata, M., Otani, Y., Kubota, T., et al. *Jpn. J. Cancer Res.* **93(7)**, 834-841 (2002).
4. Maekawa, K., Sato, H., Furukawa, M., et al. *Clin. Exp. Metastasis* **19(6)**, 513-518 (2002).
5. Skipper, J.B., McNally, L.R., Rosenthal, E.L., et al. *ORL J. Otorhinolaryngol. Relat. Spec.* **71(1)**, 1-5 (2009).
6. Barlaam, B., Bird, T.G., Lambert-Van Der Brempt, C., et al. *J. Med. Chem.* **42(23)**, 4890-4908 (1999).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM